CL2020003364A1 - Tratamiento antidiabético cardiovascular y renal seguro - Google Patents

Tratamiento antidiabético cardiovascular y renal seguro

Info

Publication number
CL2020003364A1
CL2020003364A1 CL2020003364A CL2020003364A CL2020003364A1 CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1 CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A CL2020003364 A CL 2020003364A CL 2020003364 A1 CL2020003364 A1 CL 2020003364A1
Authority
CL
Chile
Prior art keywords
renal
cardiovascular
safe
antidiabetic treatment
antidiabetic
Prior art date
Application number
CL2020003364A
Other languages
English (en)
Inventor
Eynatten Maximilian Von
Odd-Erik Johansen
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of CL2020003364A1 publication Critical patent/CL2020003364A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Diabetes (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)

Abstract

La presente invención se refiere al tratamiento antidiabético cardiovascular y renal seguro.
CL2020003364A 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro CL2020003364A1 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18184034 2018-07-17
EP18187272 2018-08-03
EP18197472 2018-09-28
EP18202843 2018-10-26
EP19177388 2019-05-29

Publications (1)

Publication Number Publication Date
CL2020003364A1 true CL2020003364A1 (es) 2021-07-02

Family

ID=67262338

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2020003364A CL2020003364A1 (es) 2018-07-17 2020-12-23 Tratamiento antidiabético cardiovascular y renal seguro

Country Status (12)

Country Link
US (2) US20200022985A1 (es)
EP (1) EP3823625A1 (es)
JP (2) JP2021530508A (es)
KR (1) KR20210035227A (es)
CN (1) CN112437666A (es)
AU (1) AU2019306036A1 (es)
BR (1) BR112020026164A2 (es)
CA (1) CA3103735A1 (es)
CL (1) CL2020003364A1 (es)
MX (1) MX2021000554A (es)
PH (1) PH12021550101A1 (es)
WO (1) WO2020016230A1 (es)

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5093330A (en) 1987-06-15 1992-03-03 Ciba-Geigy Corporation Staurosporine derivatives substituted at methylamino nitrogen
TW225528B (es) 1992-04-03 1994-06-21 Ciba Geigy Ag
CO4950519A1 (es) 1997-02-13 2000-09-01 Novartis Ag Ftalazinas, preparaciones farmaceuticas que las comprenden y proceso para su preparacion
GB0215676D0 (en) 2002-07-05 2002-08-14 Novartis Ag Organic compounds
WO2006041976A1 (en) 2004-10-08 2006-04-20 Novartis Ag Combination of organic compounds
CA2612142A1 (en) 2005-07-01 2007-01-11 Merck & Co., Inc. Process for synthesizing a cetp inhibitor
PE20080251A1 (es) 2006-05-04 2008-04-25 Boehringer Ingelheim Int Usos de inhibidores de dpp iv
WO2013171167A1 (en) * 2012-05-14 2013-11-21 Boehringer Ingelheim International Gmbh A xanthine derivative as dpp -4 inhibitor for use in the treatment of podocytes related disorders and/or nephrotic syndrome
US20140274889A1 (en) * 2013-03-15 2014-09-18 Boehringer Ingelheim International Gmbh Cardio- and renoprotective antidiabetic therapy
ES2950384T3 (es) * 2014-02-28 2023-10-09 Boehringer Ingelheim Int Uso médico de un inhibidor de DPP-4
EP4233840A3 (en) * 2016-06-10 2023-10-18 Boehringer Ingelheim International GmbH Combinations of linagliptin and metformin

Also Published As

Publication number Publication date
JP2021530508A (ja) 2021-11-11
US20200022985A1 (en) 2020-01-23
BR112020026164A2 (pt) 2021-03-23
JP2024124413A (ja) 2024-09-12
AU2019306036A1 (en) 2020-12-17
CA3103735A1 (en) 2020-01-23
CN112437666A (zh) 2021-03-02
KR20210035227A (ko) 2021-03-31
US20220160717A1 (en) 2022-05-26
EP3823625A1 (en) 2021-05-26
PH12021550101A1 (en) 2021-09-27
MX2021000554A (es) 2021-03-29
WO2020016230A1 (en) 2020-01-23

Similar Documents

Publication Publication Date Title
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
CL2022000448A1 (es) Autoinyector (divisional solicitud no. 201903061)
CL2016002455A1 (es) Anticuerpos multiespecíficos.
ZA201902141B (en) Acid-alpha glucosidase variants and uses thereof
EA201791029A1 (ru) Антитела против интерлейкина-33 и их применение
EA201792613A1 (ru) Модуляторы cot и способы их применения
MX2024004419A (es) Variantes de alfa-glucosidasa acida y usos de las mismas.
CL2020003414A1 (es) Tratamiento antidiabético cardiovascular seguro
EA201792612A1 (ru) 6-аминохинолин-3-карбонитрилы в качестве модуляторов cot
EA201591665A1 (ru) Оральные составы деферазирокса
MX2020010657A (es) Derivados de oxadiazolina.
BR112018002382A2 (pt) novos anticorpos anti-gvpi humano e usos dos mesmos
TR201901348T4 (tr) Metap-2 inhibitörleri olarak pirolidinon türevleri.
EA201700142A1 (ru) Полимерная композиция для слоя элемента слоя
MX2019010950A (es) Composicion de fotosensibilizador que contiene fenalen-1-ona, compuesto de fenalen-1-ona, asi como su uso.
EA202190475A1 (ru) Мини-gde для лечения гликогеноза iii типа
EA201692028A1 (ru) Применение замещенных оксотетрагидрохинолинилсульфонамидов или их солей для повышения стрессоустойчивости растений
EA201692569A1 (ru) Полимиксины с низкой степенью замещения и композиции, их содержащие
CL2020003364A1 (es) Tratamiento antidiabético cardiovascular y renal seguro
CL2019000572A1 (es) Compuesto de imida y uso del mismo.
UA115720U (xx) 7-n-метилбензил-8-бензиліденгідразінотеофілін, який виявляє антигіпоксичну та антиоксидантну дії
RU2015121640A (ru) Мост с компенсатором
UA114708U (uk) Тяговий привід електробуса
UA96859U (uk) Застосування рослинного збору "дента-фіт" для лікування запальних захворювань пародонта
AU365961S (en) Clasp